Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Position Increased by Green Alpha Advisors LLC

Green Alpha Advisors LLC raised its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,145 shares of the company’s stock after purchasing an additional 2,346 shares during the quarter. Green Alpha Advisors LLC’s holdings in Recursion Pharmaceuticals were worth $454,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. ARK Investment Management LLC grew its stake in shares of Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after buying an additional 4,626,268 shares in the last quarter. State Street Corp grew its position in Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after acquiring an additional 4,120,685 shares in the last quarter. FMR LLC increased its stake in shares of Recursion Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after purchasing an additional 170,810 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after purchasing an additional 656,003 shares in the last quarter. Finally, Lingotto Investment Management LLP lifted its stake in shares of Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after purchasing an additional 1,500,000 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $6.88 on Monday. The company has a market capitalization of $2.69 billion, a PE ratio of -4.50 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals, Inc. has a one year low of $5.60 and a one year high of $15.74. The company’s fifty day moving average price is $6.94 and its 200 day moving average price is $6.98.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the previous year, the firm posted ($0.43) earnings per share. The company’s revenue for the quarter was up 147.6% on a year-over-year basis. As a group, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RXRX has been the topic of several analyst reports. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.75.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49. Following the completion of the sale, the director now owns 7,089,007 shares of the company’s stock, valued at approximately $47,283,676.69. The trade was a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,341 shares of company stock worth $393,490 over the last three months. 15.75% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.